Bristol/NCI extend Taxol CRADA; new agreement worth $30 mil. per year to NIH institute.
Executive Summary
BRISTOL/NCI TAXOL AGREEMENT WORTH UP TO $30 MIL. PER YEAR to the institute, Bristol stated Dec. 4. Under the new agreement, Bristol-Myers Squibb has been granted exclusive worldwide rights to three National Cancer Institute inventions concerning Taxol (paclitaxel) for future development. Bristol and the NIH institute have also extended their Cooperative Research and Development Agreement for Taxol through December 1997. The CRADA was first signed in 1990.